Search

The article explores the Physician-Assisted Suicide (PAS) among persons with disabilities. The Oregon Death with Dignity Act that was passed in 1994 and was adopted by Washington in 2008 are some examples that legalizes PAS. Disability rights advocates strongly opposed legalization of PAS as it discriminates persons with disabilities because it creates a double standard for people with disabilities whether it is terminal or not. Political thinker Felicia Ackerman argued that PAS should only be administered to people who have a low quality of life.

Objective: To examine the relationship of ovulation-inducing drugs and ovarian cancer. Design: Retrospective cohort study, with additional follow-up since initial report. Setting: Five large reproductive endocrinology practices. Patient(s): In a retrospective cohort of 9,825 women evaluated for infertility at five clinical sites in the United States between 1965 and 1988 with follow-up through 2010, we examined the relationship of ovulation-inducing drugs and ovarian cancer (n = 85). Intervention(s): None. Main Outcome Measure(s): Hazard rate ratios (RR) and 95% confidence intervals (CI) for ovarian cancer. Result(s): Among women evaluated for infertility, there was no association of ovarian cancer risk with ever use of clomiphene citrate (CC) (adjusted RR 1.34, 95% CI 0.86–2.07) or gonadotropins (RR 1.00, 95% CI 0.48–2.08) and no evidence that any of several more detailed subgroups of usage were related to an increased risk with one exception: women who used CC and remained nulligravid did demonstrate much higher risks than those who successfully conceived compared with nonusers (respectively, RR 3.63, 95% CI 1.36–9.72 vs. RR 0.88, 95% CI 0.47–1.63). Conclusion(s): Our overall results were reassuring and consistent with other studies. A reason for an association between CC use and ovarian cancer among persistently nulligravid women remains to be determined. Given the large and increasing number of women treated with ovulation-inducing drugs, the increased risk of ovarian cancer among the subset of women who remained nulligravid should be further monitored. [Copyright &y& Elsevier]